Ginkgo Bioworks Partners with Inductive Bio and Tangible Scientific to Revolutionize AI-Driven Drug Discovery

Ginkgo Bioworks has partnered with Inductive Bio and Tangible Scientific to integrate AI-driven drug discovery workflows across the biopharma industry. The collaboration integrates ADME profiling, AI-powered chemistry design, and compound management, supporting FDA initiatives and available in Boston's biopharma hub for pharmaceutical and biotech teams. The unified platform aims to reduce synthesis cycles and accelerate development timelines, ultimately lowering costs.

Ginkgo Bioworks (NYSE: DNA), a leader in cell programming and biosecurity, has announced a strategic partnership with Inductive Bio and Tangible Scientific to integrate AI-driven drug discovery workflows across the biopharma industry. The collaboration aims to make advanced drug discovery capabilities more accessible by combining high-throughput experimental workflows, streamlined compound management, and predictive chemistry AI models into a seamless integrated service [1].

The partnership connects three core capabilities: Ginkgo Datapoints' rapid ADME profiling, Inductive Bio's model-driven chemistry design platform, and Tangible Scientific's API-enabled compound management platform. Together, these capabilities aim to move from in-silico compound designs to validated experimental results in one digitally-enabled workstream, with fewer synthesis cycles, faster turnarounds, and lower overall drug discovery costs [1].

Traditional drug discovery processes are often fragmented, involving the movement of compounds across vendors and continents, which can introduce delays and coordination bottlenecks. The new collaboration addresses these challenges by tightly coupling model-driven design with streamlined logistics to deliver AI/ML-ready assay data in real-time [1].

Ginkgo Datapoints' ADME profiling service provides high-quality readouts, including microsomal stability, kinetic solubility, P450 inhibition, and permeability, with optional in vitro toxicity readouts. Tangible Scientific's platform unifies compounds, data, and decision-making into a single, automated pipeline, enabling researchers to submit orders for Ginkgo's ADME services directly from their digital environments and receive real-time status notifications and structured, metadata-rich assay results in days, rather than weeks [1].

Inductive Bio's Compass platform allows chemists to explore and rank design ideas using fine-tuned ADMET prediction models trained on a broad consortium dataset. Designs can then be sent to Tangible and Ginkgo for experimental validation, creating a lab-in-the-loop cycle that combines predictive accuracy with real-world results [1].

The partnership aims to reduce the time and uncertainty in early-stage drug development, supporting the FDA's push for faster, more efficient development timelines, onshored manufacturing and services, greater use of AI tools, and adoption of non-animal approaches in preclinical testing [1].

The services are available now and are tailored for pharmaceutical and biotech teams looking to improve ADMET optimization and reduce iteration times on programs and across portfolios. The collaboration is a significant step towards making drug discovery more efficient and cost-effective, aligning with the industry's ongoing efforts to accelerate innovation and improve patient outcomes [1].

References:
[1] https://www.prnewswire.com/news-releases/ginkgo-datapoints-tangible-scientific-and-inductive-bio-partner-to-deploy-ai-driven-lab-in-the-loop-workflows-across-the-biopharma-industry-302533834.html